EUVIMEDEUVIMED entdecken
Crossref

Clinical outcomes and immune contexture in SMARCA4 ‐deficient gastric cancer patients

Mengyao Sun, Yun Gu, Jieti Wang, Ziqiu Zhang, Zhen Ling, Chao Lin, Hao Liu, Ruochen Li, Fei Shao, Hongyong He, Jiejie Xu iD

The Journal of Pathology · 2026

DOI: 10.1002/path.6495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, 2026. Verfasst von Mengyao Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, …. Hauptthemen laut MEDLINE: Stomach Neoplasms, Transcription Factors, Nuclear Proteins, DNA Helicases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Shanghai Pujiang Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exploiting vulnerabilities in switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complexes for cancer therapy is a promising therapeutic strategy. The SWI/SNF chromatin remodeling complex acts as a regulatory component of transcription, and our previous study found an immune‐active microenvironment and better response to immunotherapy of gastric cancer with ARID1A loss. However, little is known about the clinical significance of SMARCA4 , which encodes for another subunit of the SWI/SNF complex, in gastric cancer (GC) patients. This study analyzed the association of SMARCA4 status with clinicopathological features, survival outcomes, therapeutic response, and immune microenvironment characteristics in three independent cohorts: Zhongshan Hospital (ZSHS) cohort ( n = 442), Zhongshan Hospital immune checkpoint blockade (ZSHS‐ICB) cohort ( n = 41), and Samsung Medical Center cohort (SMC, n = 51). SMARCA4‐deficient GC patients exhibit clinicopathological features associated with enhanced tumor aggressiveness, including a higher prevalence of poorly differentiated disease ( p = 0.034), pN3 stage at diagnosis ( p = 0.059), E‐cadherin negative expression ( p < 0.001), and genomically stable (GS) and microsatellite stable/epithelial–mesenchymal transition molecular subtype (MSS/EMT) ( p < 0.001 and p < 0.001, respectively). Kaplan–Meier analysis revealed that SMARCA4 deficiency indicated poor prognosis in GC ( p < 0.001). Moreover, SMARCA4 deficiency identified a subgroup of GC patients who exhibited poor outcomes despite receiving adjuvant chemotherapy in the GS subtype ( p = 0.029). In contrast, these patients demonstrated increased sensitivity to anti‐PD‐1 therapy in both the ZSHS‐ICB ( p = 0.039) and SMC ( p = 0.062) cohorts. Immunological analysis revealed a distinct immune profile characterized by abundant but exhausted CD8 + T cells in SMARCA4‐deficient GC. In conclusion, patients with SMARCA4‐deficient GC patients demonstrated poor prognosis but improved response to immunotherapy. These observed clinical outcomes may be attributed to the immunosuppressive microenvironment, highlighting the potential for developing novel therapeutic approaches. © 2025 The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsTranscription FactorsNuclear ProteinsDNA HelicasesTumor MicroenvironmentBiomarkers, TumorHumansMaleFemaleMiddle AgedAgedAdultPrognosisImmune Checkpoint InhibitorsLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

CD8+ T cellsSMARCA4 deficiencyadjuvant chemotherapygastric cancerimmunotherapymolecular subtype

Substanzen

SMARCA4 protein, humanTranscription FactorsNuclear ProteinsDNA HelicasesBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.
  • Department of Gastrointestinal Surgery, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
  • Department of Endoscopy, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China.
  • Department of Acute Care Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
  • Department of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
  • Department of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.

ORCID-Profile: Jiejie Xu

Förderung

  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • Shanghai Pujiang Programme
  • Shanghai Municipal Natural Science Foundation
  • Clinical Research Fund of Zhongshan Hospital Fudan University
  • Shanghai Municipal Health Commission
  • Natural Science Foundation of Fujian Province
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Sun, M., Gu, Y., Wang, J., Zhang, Z., Ling, Z., Lin, C., Liu, H., Li, R., Shao, F., He, H., & Xu, J. (2026). Clinical outcomes and immune contexture in SMARCA4 ‐deficient gastric cancer patients. The Journal of Pathology. https://doi.org/10.1002/path.6495

Vancouver

Sun M, Gu Y, Wang J, Zhang Z, Ling Z, Lin C, et al. Clinical outcomes and immune contexture in SMARCA4 ‐deficient gastric cancer patients. The Journal of Pathology. 2026. doi:10.1002/path.6495

BibTeX
@article{Sun2026,
  author = {Sun, Mengyao and Gu, Yun and Wang, Jieti and Zhang, Ziqiu and Ling, Zhen and Lin, Chao and Liu, Hao and Li, Ruochen and Shao, Fei and He, Hongyong and Xu, Jiejie},
  title = {Clinical outcomes and immune contexture in SMARCA4 ‐deficient gastric cancer patients},
  journal = {The Journal of Pathology},
  year = {2026},
  doi = {10.1002/path.6495}
}
Kostenlos starten →